Patents by Inventor Omar El-Agnaf

Omar El-Agnaf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA APTAMERS AND COMPOSITIONS TARGETING ALPHA-SYNUCLEIN AND METHODS OF MAKING AND USING SAME
    Publication number: 20240124883
    Abstract: The present disclosure, in part, relates to novel, aptamers targeting ?-synuclein. The present disclosure includes methods for making and methods of using aptamers targeting ?-synuclein.
    Type: Application
    Filed: February 19, 2022
    Publication date: April 18, 2024
    Inventors: Issam Hmila, Nour Khaled Majbour, Omar El-Agnaf
  • Levels of CSF-Seeded alpha-Synuclein Oligomers reflect Parkinson's Disease Severity
    Publication number: 20240118292
    Abstract: The instant disclosure relates to methods for measuring disease progression in Parkinson's Disease and other neurodegenerative diseases.
    Type: Application
    Filed: October 11, 2023
    Publication date: April 11, 2024
    Inventor: Omar El-Agnaf
  • ENGINEERED PICOBODY TO ALPHA SYNUCLEIN
    Publication number: 20240052022
    Abstract: Alpha synuclein picobodies, which are N-terminal truncations of alpha synuclein nanobodies are provided. Methods of using alpha synuclein picobodies for diagnosing and treating synucleinopathies are also provided.
    Type: Application
    Filed: August 14, 2023
    Publication date: February 15, 2024
    Inventors: Prasanna R. Kolatkar, Zeyaul Islam, Issam Hmila, Nishant Vaikath, Omar El-Agnaf
  • ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
    Publication number: 20230365665
    Abstract: The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated ?-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated ?-synuclein and uses thereof. Uses of anti-?-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of ?-synuclein-associated neurodegenerative diseases, are also disclosed.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 16, 2023
    Inventors: Omar El-Agnaf, Nour Khaled Majbour, Nishant Vaikath
  • ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED ALPHA-SYNUCLEIN AGGREGATES
    Publication number: 20220089708
    Abstract: The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated ?-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated ?-synuclein and uses thereof. Uses of anti-?-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of ?-synuclein-associated neurodegenerative diseases, are also disclosed.
    Type: Application
    Filed: October 26, 2021
    Publication date: March 24, 2022
    Inventors: Omar El-Agnaf, Nour Khaled Majbour, Nishant Vaikath
  • Alpha-synuclein antibodies and uses thereof
    Patent number: 10208111
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 19, 2019
    Assignee: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • Alpha-Synuclein Antibodies and Uses Thereof
    Publication number: 20170190765
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Application
    Filed: November 18, 2016
    Publication date: July 6, 2017
    Applicant: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • Alpha-synuclein antibodies and uses thereof
    Patent number: 9534044
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 3, 2017
    Assignee: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
    Publication number: 20140241987
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Application
    Filed: February 28, 2013
    Publication date: August 28, 2014
    Applicant: United Arab Emirates University
    Inventor: Omar EL-AGNAF
  • ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
    Publication number: 20140241984
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 28, 2014
    Applicant: UNITED ARAB EMIRATES UNIVERSITY
    Inventor: OMAR EL-AGNAF
  • Method of identifying whether or not an individual has Parkinson's Disease rather than another neurodegenerative disease
    Patent number: 8778334
    Abstract: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of ?-synuclein (?-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of ?-syn, and thereby determining whether or not the individual has PD.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: July 15, 2014
    Assignees: United Arab Emirates University, Universita Degli Studi di Perugia
    Inventors: Omar El-Agnaf, Lucilla Parnetti, Paolo Calabresi
  • Diagnostic agent
    Patent number: 8613905
    Abstract: The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: December 24, 2013
    Assignee: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • METHOD FOR DIAGNOSIS
    Publication number: 20130183278
    Abstract: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of ?-synuclein (?-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of ?-syn, and thereby determining whether or not the individual has PD.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 18, 2013
    Applicant: United Arab Emirates University
    Inventors: Omar El-Agnaf, Lucilla Parnetti, Paolo Calabresi
  • DIAGNOSTIC AGENT FOR PARKINSON'S DISEASE
    Publication number: 20120190652
    Abstract: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD in the pre-symptomatic phase of the disease or to distinguishing PD from another neurological disorder. The method of the invention comprises measuring the amount of soluble ?-synuclein oligomers in a cerebrospinal fluid sample taken from an individual. The method optionally also comprises measuring the total amount of ?-synuclein in the CSF sample, calculating the ratio of the amount of ?-synuclein oligomers to the total amount of ?-synuclein, and thereby determining whether or not the individual has PD. The method of the invention can be used in clinical trials to measure the effect of drugs in both PD animal models and human PD patients.
    Type: Application
    Filed: September 13, 2010
    Publication date: July 26, 2012
    Applicant: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • DIAGNOSTIC AGENT
    Publication number: 20100284934
    Abstract: The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease.
    Type: Application
    Filed: August 29, 2008
    Publication date: November 11, 2010
    Applicant: United Arab Emirates University
    Inventor: Omar El-Agnaf